证券代码：688222 证券简称：成都先导 公告编号：2025-053 成都先导药物开发股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 18 日 （星期二） 至 11 月 24 日 （星期 一）前登录上证路演中心网站首页点击"提问预征集"栏目或通过投 资者关系邮箱（investors@hitgen.com）进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年 第三季度经营成果、财务状况，公司计划于 2025 年 11 月 25 日(星期 二) 11:00-12:00 举行 2025 年第三季度业绩说明会，就投资者关心的 问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式 ...

Summary of Key Points Core Viewpoint - The announcement details the shareholding and reduction plan of Chengdu XianDao Pharmaceutical Development Co., Ltd., specifically regarding the share reduction by its shareholder Shenzhen JunTian Investment Enterprise (Limited Partnership) Group 1: Shareholding Information - Before the reduction plan, Shenzhen JunTian held 11,927,164 shares, accounting for 2.98% of the company's total share capital, with these shares being tradable since April 16, 2021 [1] Group 2: Reduction Plan Implementation - On August 5, 2025, the company disclosed a plan for Shenzhen JunTian to reduce its holdings by 2,000,000 shares, representing approximately 0.50% of the total share capital, to be executed within three months starting from August 8, 2025 [1] - By November 7, 2025, Shenzhen JunTian had reduced its holdings by 1,859,413 shares, which is 0.46% of the total share capital, leaving it with 10,067,751 shares, or 2.51% of the total [2] Group 3: Compliance and Results - The actual reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [4]

Core Points - Chengdu Xian Dao announced that shareholder Shenzhen Jun Tian Investment Enterprise (Limited Partnership) holds 11,927,164 shares, accounting for 2.98% of the total share capital [2] - During the reduction plan period, Shenzhen Jun Tian has cumulatively reduced its holdings by 1,859,413 shares through centralized bidding, representing 0.46% of the total share capital [2] - After the reduction, Shenzhen Jun Tian holds 10,067,751 shares, which is 2.51% of the total share capital [2]

Group 1 - The core point of the article is that Chengdu Xian Dao (688222.SH) announced a share reduction by its shareholder Shenzhen Jun Tian, who reduced their holdings by 1.8594 million shares, accounting for 0.46% of the company's total share capital [1]

证券代码：688222 证券简称：成都先导 公告编号：2025-052 成都先导药物开发股份有限公司 股东深圳市钧天投资企业（有限合伙） 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，成都先导药物开发股份有限公司（以下简称"公司"） 股东深圳市钧天投资企业（有限合伙）（以下简称"深圳钧天"）持有公司股份 11,927,164 股，占公司总股本的 2.98%。上述股份为公司 IPO 前取得股份，该 部分股份于 2021 年 4 月 16 日起解禁上市流通。 减持计划的实施结果情况 公司于 2025 年 8 月 5 日在上海证券交易所网站披露《关于股东减持股份计 划公告》（公告编号：2025-029）： 深圳钧天拟通过集中竞价交易的方式减持其所持有的公司股份合计 2,000,000 股，拟减持股份占公司总股本的比例约为 0.50%，自减持计划发布之 日起 3 个交易日之后的 3 个月内（2025 年 8 月 8 日至 2025 年 11 月 ...

Group 1 - The core point of the article is that Chengdu Xian Dao (SH 688222) announced a share reduction by its shareholder Shenzhen Jun Tian, which involved a total of approximately 1.8594 million shares, accounting for 0.46% of the company's total share capital [1] - The revenue composition for Chengdu Xian Dao in 2024 is reported to be 99.95% from scientific research and technical services, with other businesses contributing only 0.05% [1] - As of the report, Chengdu Xian Dao has a market capitalization of 9.3 billion yuan [1]

Core Viewpoint - Chengdu Xian Dao announced that its shareholder, Shenzhen Jun Tian Investment Enterprise (Limited Partnership), has reduced its stake in the company by 1,859,413 shares, representing 0.46% of the total share capital [1] Summary by Sections Shareholding Changes - After the reduction, Shenzhen Jun Tian Investment Enterprise (Limited Partnership) holds 10,067,751 shares, which is 2.51% of the total share capital [1] - The reduction price ranged from 24.01 to 30.05 yuan per share, with a total amount of 49.1493 million yuan [1] Reduction Plan Details - The reduction plan was disclosed on August 5, 2025, with an original plan to reduce no more than 2,000,000 shares, approximately 0.50% of the total share capital [1] - The intended reduction period was from August 8, 2025, to November 7, 2025, but the actual reduction occurred from August 28, 2025, to November 3, 2025 [1] - The uncompleted portion of the reduction plan is 140,587 shares [1]

Investment Rating - The investment rating for Chengdu Xian Dao (688222.SH) is "Outperform the Market" [5][3]. Core Views - The company achieved significant revenue and profit growth in the first three quarters of 2025, with revenue reaching 370 million yuan (+23.98%) and net profit attributable to shareholders at 93 million yuan (+208.34%) [8][3]. - The core business and self-developed pipeline are progressing smoothly, with clinical trials for HG146 targeting solid tumors advancing well [19][3]. - The "DEL+AI+Automation" platform has shown promising results, enhancing drug discovery and optimization processes [20][3]. Summary by Sections Financial Performance - In the first three quarters of 2025, the company reported revenue of 370 million yuan, a year-on-year increase of 23.98%, and a net profit of 93 million yuan, up 208.34% [8][3]. - The third quarter alone saw revenue of 143 million yuan (+37.89%) and net profit of 43 million yuan (+114.98%) [8][3]. - The overall gross margin for the first three quarters was 54.9%, an increase of 5.5 percentage points, and the net profit margin was 25.1%, up 15 percentage points [13][3]. Business Development - The core business has seen continuous growth, with an increase in commercial projects and successful collaborations with global partners [19][3]. - The DEL and FBDD/SBDD segments have achieved milestone payments from various projects [23][3]. - The company has initiated two new self-developed projects, leveraging the "DEL+AI+Automation" platform for drug discovery [20][3]. Future Outlook - The revenue forecasts for 2025-2027 are projected at 505 million yuan, 608 million yuan, and 744 million yuan, representing year-on-year growth rates of 18.3%, 20.5%, and 22.3% respectively [3][4]. - The net profit forecasts for the same period are 103 million yuan, 124 million yuan, and 152 million yuan, with growth rates of 99.7%, 20.5%, and 22.6% respectively [3][4]. - The current price-to-earnings ratios are projected at 94.4, 78.3, and 63.9 for 2025, 2026, and 2027 respectively [3][4].

Core Viewpoint - Chengdu XianDao's stock price has seen a significant increase of 92.99% year-to-date, despite a recent decline in the last five trading days [1][2]. Company Overview - Chengdu XianDao Pharmaceutical Development Co., Ltd. was established on February 22, 2012, and went public on April 16, 2020. The company specializes in drug discovery services using its core DEL technology and new drug development project transfers [1]. - The company's main revenue source is drug research and development services, accounting for 99.97% of total revenue, with customized services making up 59.92% [1]. Financial Performance - For the period from January to September 2025, Chengdu XianDao reported a revenue of 370 million yuan, representing a year-on-year growth of 23.98%. The net profit attributable to the parent company was 92.87 million yuan, showing a substantial increase of 208.34% [2]. - The company has distributed a total of 134 million yuan in dividends since its A-share listing, with 43.94 million yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Chengdu XianDao increased by 13.63% to 20,700, while the average circulating shares per person decreased by 11.99% to 19,312 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 9.15 million shares, an increase of 7.20 million shares compared to the previous period [3].

Group 1 - The CRO index experienced fluctuations and a downward trend on November 4th [1] - Among the constituent stocks, Shengnuo Bio, Hongbo Pharmaceutical, and Chengdu XianDao had the largest declines, with decreases of 3.80%, 3.79%, and 3.53% respectively [1]